Treatment options for the eradication of intestinal protozoa

被引:60
作者
Farthing, Michael J. G. [1 ]
机构
[1] St Georges Univ London, London SW17 0RE, England
来源
NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY | 2006年 / 3卷 / 08期
关键词
albendazole; antiprotozoal agents; diarrhea; intestinal protozoa; nitazoxanide;
D O I
10.1038/ncpgasthep0557
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Pathogenic intestinal protozoa are responsible for clinically important infections in both the developed and the developing world. These organisms are responsible for both acute and chronic diarrhea, and Entamoeba histolytica, which affects the colon, can spread to involve the liver. Many of these pathogens, particularly the intracellular protozoa that predominantly affect the small intestine, produce their most devastating effects in patients with HIV/AIDS and other forms of immune deficiency. There are also various intestinal protozoa that do not seem to have any adverse effects on humans and can, therefore, be regarded as harmless commensal organisms. Although treatment has been available for several decades for giardiasis, isosporiasis and amoebiasis, until recently there have been no effective remedies for infection with intestinal coccidia-Cryptosporidium, Microsporidium and Cyclospora species. Cyclospora respond well to co-trimoxazole, microsporidia respond variably to albendazole, and cryptosporidia can often be eradicated by nitazoxanide. In chronically infected HIV-positive patients, treatment with multidrug regimens usually results in rapid resolution of the diarrhea and, in many instances, eradication of the parasite.
引用
收藏
页码:436 / 445
页数:10
相关论文
共 79 条
[1]   Successful treatment of metronidazole- and albendazole-resistant giardiasis with nitazoxanide in a patient with acquired immunodeficiency syndrome [J].
Abboud, P ;
Lemée, V ;
Gargala, G ;
Brasseur, P ;
Ballet, JJ ;
Borsa-Lebas, F ;
Caron, F ;
Favennec, L .
CLINICAL INFECTIOUS DISEASES, 2001, 32 (12) :1792-1794
[2]   THE BIOLOGY OF GIARDIA SPP [J].
ADAM, RD .
MICROBIOLOGICAL REVIEWS, 1991, 55 (04) :706-732
[3]   Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomised controlled trial [J].
Amadi, B ;
Mwiya, M ;
Musuku, J ;
Watuka, A ;
Sianongo, S ;
Ayoub, A ;
Kelly, P .
LANCET, 2002, 360 (9343) :1375-1380
[4]   Intestinal protozoa in HIV-infected patients:: Effect of rifaximin in Cryptosporidium parvum and Blastocystis hominis infections [J].
Amenta, M ;
Dalle Nogare, ER ;
Colomba, C ;
Prestileo, TS ;
Di Lorenzo, F ;
Fundarò, S ;
Colomba, A ;
Ferrieri, A .
JOURNAL OF CHEMOTHERAPY, 1999, 11 (05) :391-395
[5]  
Anderson KA, 2004, CAN VET J, V45, P924
[6]  
AREAN VM, 1956, AM J PATHOL, V32, P1089
[7]   Nitazoxanide treatment for giardiasis and cryptosporidiosis in children [J].
Bailey, JM ;
Erramouspe, J .
ANNALS OF PHARMACOTHERAPY, 2004, 38 (04) :634-640
[8]   Infectivity of Cryptosporidium hominis and Cryptosporidium parvum genotype 2 isolates in immunosuppressed Mongolian gerbils [J].
Baishanbo, A ;
Gargala, G ;
Delaunay, A ;
François, A ;
Ballet, JJ ;
Favennec, L .
INFECTION AND IMMUNITY, 2005, 73 (08) :5252-5255
[9]   THE PREVALENCE OF INVASIVE AMEBIASIS IS NOT INCREASED IN PATIENTS WITH AIDS [J].
JESSURUN, J ;
BARRONRODRIGUEZ, LP ;
FERNANDEZTINOCO, G ;
HERNANDEZAVILA, M .
AIDS, 1992, 6 (03) :307-309
[10]  
BOREHAM PFL, 1992, GIARDIA MOL DIS, P317